Country: Bandaríkin
Tungumál: enska
Heimild: NLM (National Library of Medicine)
Erythromycin (UNII: 63937KV33D) (Erythromycin - UNII:63937KV33D)
E. FOUGERA & CO.
Erythromycin
SOLUTION
20 mg
TOPICAL
PRESCRIPTION DRUG
Erythromycin pledgets, USP are indicated for the topical treatment of acne vulgaris. Erythromycin pledgets, USP are contraindicated in those individuals who have shown hypersensitivity to any of its components.
Each pledget is filled to contain 1 mL of Erythromycin Topical Solution USP 2%. Each mL of Erythromycin Topical Solution USP 2% contains 20 mg of erythromycin. Each pledget is supplied in an individual foil packet in boxes of 60. NDC 0168-0215-01. Store at 20°- 25°C (68°- 77°F)[See USP Controlled Room Temperature]. E. FOUGERA & CO. a division of Altana Inc. MELVILLE, NY 11747 IF221501 R6/06 #46 Remove this portion before dispensing ERYTHROMYCIN PLEDGETS, USP
ERYTHROMYCIN- ERYTHROMYCIN SOLUTION E. FOUGERA & CO. ---------- ERYTHROMYCIN PLEDGETS, USP FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC USE Rx only DESCRIPTION Erythromycin Pledgets, USP contains erythromycin ((3_R_*,4_S_*,5_S_*,6_R_*,7_R_*,9_R_*,11_R_*,12_R_*,13_S_*,14_R_*)- 4-[(2,6-Dideoxy-3-_C_-methyl-3-_O_-methyl-α_-_ -_ribo_-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy 3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-d-_xylo_- hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatologic use. Erythromycin is a macrolide antibiotic produced from a strain of _Saccharopolyspora erythraea_ (formerly _Streptomyces_ _erythreus_). It is a base and readily forms salts with acids. Chemically, erythromycin is C H NO . It has the following structural formula: Erythromycin has the molecular weight of 733.94 It is a white powder, is freely soluble in alcohols, acetone, chloroform, acetonitrile, ethyl acetate, and moderately soluble in ether, ethylene dichloride and amyl acetate. Erythromycin pledgets, USP are absorbent pads impregnated with Erythromycin Topical Solution 2%. Each pledget contains 1 mL of Erythromycin Topical Solution 2% and each 1 mL of Erythromycin Topical Solution 2% contains 20 mg of erythromycin base in a vehicle consisting of alcohol (71.5% v/v) and propylene glycol. May contain anhydrous citric acid and/or alcohol to adjust pH. CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug. MICROBIOLOGY: Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50 S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer- RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated _in vitro_ between erythromycin, lincomycin, chloramphenicol, and clindamycin. INDICATIONS AND USAGE Erythromycin pledgets, USP are indicated for the topical treatment of Lestu allt skjalið